INVESTIGATION OF THE EFFECT OF DIFFERENT ACTIVATION TECHNIQUES ON TLR9, IL6, IL10, TNF-ALFA LEVELS IN HEALTHY AND TYPE 2 DIABETIC PATIENTS WITH APICAL PERIODONTITIS REQUIRING RETREATMENT
TLR9 in T2DM
1 other identifier
observational
90
1 country
1
Brief Summary
The subject of this thesis study is the effects of SWEEPS laser and ultrasonic activation methods on the immune response in the treatment of apical periodontitis in healthy individuals and patients with Type 2 diabetes requiring retreatment, based on a comparative investigation of Toll-like Receptor 9 (TLR-9), Interleukin-6 (IL-6) and Tumour Necrosis Factor alpha (TNF-α), and Interleukin-10 (IL-10) levels.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2026
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 28, 2026
CompletedFirst Submitted
Initial submission to the registry
January 29, 2026
CompletedFirst Posted
Study publicly available on registry
February 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 15, 2027
February 10, 2026
January 1, 2026
5 months
January 29, 2026
February 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
TLR9 expression levels in periapical exudate and gingival crevicular fluid samples
TLR9 will be measured in periapical exudate and gingival crevicular fluid (GCF) samples obtained during routine root canal treatment. The analysis will be performed using the ELISA method. The aim is to compare expression levels between healthy individuals and patients with type 2 diabetes mellitus.
Immediately after the procedure
Secondary Outcomes (1)
Correlation analysis between TLR9, IL6, IL10, and TNF-α levels in periapical exudate and gingival crevicular fluid samples
Immediately after the procedure
Study Arms (2)
healty group
Patients included in the study will be randomly assigned to two main groups using www.randomizer.org. DOS samples will be collected in both the control and experimental groups during both sessions. A total of 90 patients will be divided into two main groups: systemically healthy individuals (n=45) and patients with type 2 diabetes (n=45). Each main group will be divided into three subgroups (n=15) according to the irrigation protocol applied: conventional irrigation, ultrasonic activation , and SWEEPS laser activation . Periapical exudate samples will be collected from all patients in both sessions.
type 2 diabet mellitus group
Patients included in the study will be randomly assigned to two main groups using www.randomizer.org. DOS samples will be collected in both the control and experimental groups during both sessions. A total of 90 patients will be divided into two main groups: systemically healthy individuals (n=45) and patients with type 2 diabetes (n=45). Each main group will be divided into three subgroups (n=15) according to the irrigation protocol applied: conventional irrigation, ultrasonic activation , and SWEEPS laser activation . Periapical exudate samples will be collected from all patients in both sessions.
Eligibility Criteria
This study will include patients aged 18-64 years who present to the Department of Endodontics, Faculty of Dentistry, Kırıkkale University, with an indication for root canal therapy and are diagnosed with either a healthy group(Group 1) or type 2 diabet mellitus (Group 2).
You may qualify if:
- Patients aged 18-50 years
- Patients with ASA I status
- Patients with Type 2 diabetes whose HbA1c values are between 5.5% and 9.0%, with diabetes diagnosis confirmed by medical history and laboratory tests (HbA1c test)
- Upper and lower incisors and lower premolars with chronic apical periodontitis,
- Teeth requiring retreatment with a PAI score ≥3 will be included in the study. (15)
You may not qualify if:
- ASA II or higher,
- Pregnant women or those suspected of being pregnant,
- Patients with localized or generalized periodontitis,
- Patients with inflammatory or autoimmune diseases such as hepatitis, HIV infection, immunosuppressive chemotherapy, bleeding disorders, Behçet's syndrome, and arthritis,
- Individuals with HbA1c levels above 9%,
- \. Those who have used antibiotics within the last month and anti-inflammatory drugs within the last week, 6. Smokers, 7. Patients with periodontal pockets greater than 3 mm in the relevant tooth, 8. Those with internal or external root resorption, 9. Those with swelling, palpation pain, or a fistula in the relevant area, 10. Those with root fracture or incomplete root formation, 11. Teeth that cannot be isolated with a rubber dam will not be included in the study.
- The name, surname, age, gender, contact information, and tooth number to be treated of patients included in the study will be recorded on the case report form. Periapical radiographs will be taken of the relevant teeth prior to root canal treatment to examine the root canal anatomy. The periapical health status of each tooth will be assessed using the PAI score.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- bengisu yüksellead
Study Sites (1)
Kirikkale University Faculty of Dentistry
Kırıkkale, Kırıkkale, 71450, Turkey (Türkiye)
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
dilek hancerliogulları, associate professor
Kırıkkale University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- phd student
Study Record Dates
First Submitted
January 29, 2026
First Posted
February 5, 2026
Study Start
January 28, 2026
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
May 15, 2027
Last Updated
February 10, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share